Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
Healthcare
$9.24 -3.20%
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
52W Low $3.69High $16.33
Volume 0.20M
Average 0.26M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$55.31M
FY 2025 · Annual
Investing Cash Flow
-$3.71M
FY 2025 · Annual
Financing Cash Flow
$112.69M
FY 2025 · Annual
+3.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29M) | (24.25M) | 22.72M | (42.26M) | (59.98M) |
| Depreciation & Amortization | 325K | 329K | 195K | 258K | 323K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.75M | 1.93M | 2.22M | 6.8M | 10.04M |
| Change in Working Capital | 108K | (1.27M) | (1.02M) | 5.33M | (6.04M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (110K) | (230K) | 0 | 1.14M | (869K) |
| Other Working Capital | 218K | (1.04M) | (1.02M) | 4.19M | (5.17M) |
| Other Non-Cash Items | 553K | 3.14M | (4.76M) | (2.98M) | 344K |
| Operating Cash Flow | (26.27M) | (20.12M) | 19.35M | (32.85M) | (55.31M) |
| Capital Expenditures | (168K) | (118K) | (414K) | (514K) | (231K) |
| Acquisitions (Net) | 0 | 0 | 0 | 20K | 0 |
| Purchases of Investments | (66.78M) | (64.7M) | (141.87M) | (226.41M) | (162.5M) |
| Sales of Investments | 1.98M | 87.12M | 76.71M | 157.16M | 159.02M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (64.97M) | 22.3M | (65.57M) | (69.74M) | (3.71M) |
| Debt Repayment | 0 | (1.25M) | (3.75M) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 108.21M | 112.69M |
| Common Stock Repurchased | 0 | (4K) | (28K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 113K | 15K | (184K) | 790K | 0 |
| Financing Cash Flow | 79.84M | (1.24M) | 56.18M | 109M | 112.69M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.4M) | 939K | 9.96M | 6.42M | 53.66M |
| Free Cash Flow | (26.43M) | (20.24M) | 18.94M | (33.36M) | (55.54M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$60.0M
+ D&A$323.0K
+ Stock-Based Comp$10.0M
+ Deferred Tax$0
- Working Capital-$6.0M
+ Other Non-Cash$344.0K
= Operating Cash Flow-$55.3M
- Capex-$231.0K
= Free Cash Flow-$55.5M
Analysis
FY2025 free cash flow is -$55.5M. FCF conversion is 92.6% of net income. Operating cash flow was -$55.3M, with capex of -$231.0K. The largest bridge item is Stock-Based Comp at $10.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13G | SC 13G filing | Oct 28, 2026 |
Does CTNM generate free cash flow?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) generated -$55.54M of free cash flow in fiscal 2025.
How much operating cash flow does CTNM produce?
Operating cash flow was -$55.31M, before capital expenditures of $231,000.00.
Continue the stock analysis
Jump to another research area for this company.